BRAF and neoplasm: Our long-term follow-up of in vivo growth of IC-3635PXA tumors revealed a clear enrichment of BRAF V600E mutation frequency and detected a novel a shift of diploid chromosome 9 to trisomy 9 in tumor cells bearing CDKN2A deletion.